UCB SA (UCB)

99.02
+0.30(+0.30%)
  • Volume:
    231,517
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    98.68 - 99.84
  • Type:Equity
  • Market:Belgium
  • ISIN:BE0003739530

UCB Overview

Prev. Close
98.72
Day's Range
98.68-99.84
Revenue
5.52B
Open
99.12
52 wk Range
74.32-107.4
EPS
4.77
Volume
231,517
Market Cap
18.7B
Dividend (Yield)
0.89
(0.90%)
Average Volume (3m)
241,635
P/E Ratio
20.77
Beta
0.43
1-Year Change
11.66%
Shares Outstanding
188,811,567
Next Earnings Date
24 Feb 2022
What is your sentiment on UCB SA?
or
Market is currently closed. Voting is open during market hours.

  • UCB Earnings miss, Revenue beats In Q2
    • ByInvesting.com-

    Investing.com - UCB reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that topped expectations. UCB announced earnings per share of...

  • UCB Earnings miss, Revenue Inline In Q2
    • ByInvesting.com-

    Investing.com - UCB reported on Monday second quarter earnings that missed analysts' forecasts and revenue that was inline with expectations. UCB announced earnings per share of...

UCB SA Company Profile

Employees
7600
Market
Belgium

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellNeutralBuyStrong Buy
Technical IndicatorsSellSellBuySellStrong Buy
SummaryStrong SellSellNeutralNeutralStrong Buy
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.